Keiko Ohgino

838 total citations
24 papers, 471 citations indexed

About

Keiko Ohgino is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Keiko Ohgino has authored 24 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Molecular Biology and 8 papers in Oncology. Recurrent topics in Keiko Ohgino's work include Lung Cancer Treatments and Mutations (11 papers), Fibroblast Growth Factor Research (4 papers) and Epigenetics and DNA Methylation (4 papers). Keiko Ohgino is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Fibroblast Growth Factor Research (4 papers) and Epigenetics and DNA Methylation (4 papers). Keiko Ohgino collaborates with scholars based in Japan, France and United States. Keiko Ohgino's co-authors include Kenzo Soejima, Kota Ishioka, Tomoko Betsuyaku, Daisuke Arai, Katsuhiko Naoki, Takashi Sato, Shinnosuke Ikemura, Hiroyuki Yasuda, Hideki Terai and Junko Hamamoto and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and Cancer Science.

In The Last Decade

Keiko Ohgino

21 papers receiving 468 citations

Peers

Countries citing papers authored by Keiko Ohgino

Since Specialization

Citations

This map shows the geographic impact of Keiko Ohgino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keiko Ohgino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keiko Ohgino more than expected).

Fields of papers citing papers by Keiko Ohgino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keiko Ohgino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keiko Ohgino. The network helps show where Keiko Ohgino may publish in the future.

Co-authorship network of co-authors of Keiko Ohgino

This figure shows the co-authorship network connecting the top 25 collaborators of Keiko Ohgino. A scholar is included among the top collaborators of Keiko Ohgino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keiko Ohgino. Keiko Ohgino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Acquisition of FGFR1 and NSD3 Amplifications During the Transformation of EGFR-Mutated Lung Adenocarcinoma into Squamous Cell Carcinoma: A Case Report 2025 ·JTO Clinical and Research Reports ·Noritaka Fukunaga, Hideki Terai, (unknown), Yutaka Kurebayashi, Kohei Nakamura, Ryutaro Kawano, Kohei Shigeta, Koji Okabayashi, (unknown), Akihiko Ogata, (unknown), (unknown), (unknown), (unknown), Shigenari Nukaga, Keiko Ohgino, Hiroyuki Yasuda, Hiroshi Nishihara, Yuko Kitagawa, Koichi Fukunaga	0
2	Initial single-institutional experience with salvage surgery for stage IV non-small-cell lung cancer 2025 ·Interdisciplinary CardioVascular and Thoracic Surgery ·Tomoyuki Hishida, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Keiko Ohgino, Hideki Terai, Hiroyuki Yasuda, Keisuke Asakura	0
3	Clinical features of Japanese patients with gastrointestinal long‐COVID symptoms 2023 ·JGH Open ·Kazuma Yagi, Takanori Asakura, Hideki Terai, Keiko Ohgino, Katsunori Masaki, Ho Namkoong, Shotaro Chubachi, Jun Miyata, Ichiro Kawada, Nobuhiro Kodama, Satoshi Sakamoto, Akira Umeda, Takashi Ishiguro, Makoto Ishii, Koichi Fukunaga	2
4	Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis 2022 ·Clinical Lung Cancer ·(unknown), Yoshitaka Oyamada, Shinnosuke Ikemura, Shigenari Nukaga, (unknown), Daisuke Arai, Keiko Ohgino, (unknown), Kota Ishioka, Fumio Sakamaki, Yusuke Suzuki, Hideki Terai, Hiroyuki Yasuda, Ichiro Kawada, Koichi Fukunaga, Kenzo Soejima	4
5	Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer 2021 ·Cancer Management and Research ·Tetsuo Tani, Ichiro Nakachi, Shinnosuke Ikemura, Shigenari Nukaga, Keiko Ohgino, (unknown), Hideki Terai, Keita Masuzawa, (unknown), Kota Ishioka, Yohei Funatsu, Hidefumi Koh, Koichi Fukunaga, Kenzo Soejima	6
6	Adult cases of late-onset congenital central hypoventilation syndrome and paired-like homeobox 2B-mutation carriers: an additional case report and pooled analysis 2020 ·Journal of Clinical Sleep Medicine ·(unknown), Jiro Terada, Hajime Kasai, (unknown), Keiko Ohgino, Ayako Sasaki, Kiyoshi Hayasaka, Koichiro Tatsumi	8
7	Intracellular levels of reactive oxygen species correlate with ABT‐263 sensitivity in non‐small‐cell lung cancer cells 2020 ·Cancer Science ·Keiko Ohgino, Hideki Terai, Hiroyuki Yasuda, Shigenari Nukaga, Junko Hamamoto, Tetsuo Tani, (unknown), Daisuke Arai, Kota Ishioka, Keita Masuzawa, Shinnosuke Ikemura, Ichiro Kawada, Katsuhiko Naoki, Koichi Fukunaga, Kenzo Soejima	8
8	A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients 2019 ·Cancer Chemotherapy and Pharmacology ·Tetsuo Tani, Katsuhiko Naoki, Hiroyuki Yasuda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Hideki Terai, Shinnosuke Ikemura, Takashi Sato, Kenzo Soejima	1
9	Drug-induced pneumonitis following the administration of laninamivir octanoate: The first two reported cases 2019 ·Journal of Infection and Chemotherapy ·(unknown), (unknown), Keiko Ohgino, (unknown), Tomoko Betsuyaku, Koichi Sayama	1
10	Detection of EGFR T790M in a Large Amount of Malignant Ascites Cellblock. 2018 ·PubMed ·Kota Ishioka, Shinji Sasada, Keiko Ohgino, Tetsuya Sakai, Saeko Takahashi, (unknown), (unknown), Morio Nakamura	1
11	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer 2016 ·Molecular Cancer Research ·Masayoshi Miyawaki, Hiroyuki Yasuda, Tetsuo Tani, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Shigenari Nukaga, Toshiyuki Hirano, Ichiro Kawada, Katsuhiko Naoki, Yuichiro Hayashi, Tomoko Betsuyaku, Kenzo Soejima	58
12	Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK -Translocated Lung Cancer Cells 2015 ·Molecular Cancer Therapeutics ·Tetsuo Tani, Hiroyuki Yasuda, Junko Hamamoto, (unknown), Daisuke Arai, Kota Ishioka, Keiko Ohgino, Masayoshi Miyawaki, Ichiro Kawada, Katsuhiko Naoki, Yuichiro Hayashi, Tomoko Betsuyaku, Kenzo Soejima	54
13	A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer 2015 ·Japanese Journal of Clinical Oncology ·Shinnosuke Ikemura, Katsuhiko Naoki, Hiroyuki Yasuda, Ichiro Kawada, Satoshi Yoda, Hideki Terai, Takashi Sato, Kota Ishioka, Daisuke Arai, Keiko Ohgino, Hirofumi Kamata, Jun Miyata, Hiroki Kabata, Tomoko Betsuyaku, Kenzo Soejima	6
14	Prognostic implication of PTPRH hypomethylation in non-small cell lung cancer 2015 ·Oncology Reports ·Takashi Sato, Kenzo Soejima, Eri Arai, Junko Hamamoto, Hiroyuki Yasuda, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Katsuhiko Naoki, Takashi Kohno, Koji Tsuta, Shun-ichi Watanabe, Yae Kanai, Tomoko Betsuyaku	21
15	Abstract 4: ABT-263 is effective in a subset of non-small cell lung cancer cell lines 2015 ·Cancer Research ·(unknown), Keiko Ohgino, Hiroyuki Yasuda, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Tetsuo Tani, Shigenari Nukaga, Ichiro Kawada, Katsuhiko Naoki, Kenzo Soejima, Tomoko Betsuyaku	4
16	Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line 2014 ·International Journal of Oncology ·Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Takashi Sato, Katsuhiko Naoki, Shinnosuke Ikemura, Daisuke Arai, Keiko Ohgino, Kota Ishioka, Junko Hamamoto, Yae Kanai, Tomoko Betsuyaku	12
17	Multiple roles of extracellular fibroblast growth factors in lung cancer cells 2014 ·International Journal of Oncology ·Takahiro Suzuki, Hiroyuki Yasuda, (unknown), Daisuke Arai, Kota Ishioka, Keiko Ohgino, Tetsuo Tani, Junko Hamamoto, (unknown), Katsuhiko Naoki, Tomoko Betsuyaku, Kenzo Soejima	16
18	Methylation‐induced downregulation of TFPI‐2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non‐small‐cell lung carcinoma 2014 ·Cancer Science ·Junko Hamamoto, Kenzo Soejima, Katsuhiko Naoki, Hiroyuki Yasuda, Yuichiro Hayashi, Satoshi Yoda, Sohei Nakayama, Ryosuke Satomi, Hideki Terai, Shinnosuke Ikemura, Takashi Sato, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Tomoko Betsuyaku	17
19	Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC 2013 ·Molecular Cancer Research ·Hideki Terai, Kenzo Soejima, Hiroyuki Yasuda, Sohei Nakayama, Junko Hamamoto, Daisuke Arai, Kota Ishioka, Keiko Ohgino, Shinnosuke Ikemura, Takashi Sato, Satoshi Yoda, Ryosuke Satomi, Katsuhiko Naoki, Tomoko Betsuyaku	174
20	Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer 2013 ·Lung Cancer ·Keiko Ohgino, Kenzo Soejima, Hiroyuki Yasuda, Yuichiro Hayashi, Junko Hamamoto, Katsuhiko Naoki, Daisuke Arai, Kota Ishioka, Takashi Sato, Hideki Terai, Shinnosuke Ikemura, Satoshi Yoda, Tetsuo Tani, (unknown), Tomoko Betsuyaku	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact